CGT

1,163개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,163 programs
CGTLimited DatastaleBambino Gesù Hospital and Resea…Phase 1

iC9-GD2-CAR T-cells (GD2-CART01, GD2-CART01 (iC9-GD2-CAR T-cells))

Brain Tumor, Pediatric; Medulloblastoma, Childhood · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

GD2-targeted CAR-T cells (GD2-targeted CAR-T cells)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 2

GEM/DOX + TGFBi expanded NK cells (GEM/DOX + TGFBi expanded NK cells)

Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLakefront Biotherapeutics NVPhase 3

GLPG CAR T-cell therapy (GLPG CAR T-cell therapy)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

GLYCAR T cells (GLYCAR T cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

GPC3 CD146 CAR-T cells (GPC3 CD146 CAR-T cells)

Ovarian Cancer; Ovarian Carcinoma · Ovarian Cancer

#OvarianCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

GPC3 and/or TGFβ targeting CAR-T cells (GPC3 and/or TGFβ targeting CAR-T cells)

Hepatocellular Carcinoma; Immunotherapy · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

GPC3-CART cells (GPC3-CART cells)

Hepatocellular Carcinoma (HCC) · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 1

GPRC5D-CAR-T (GPRC5D-CAR-T)

Multiple Myeloma · GPRC5D

#GPRC5D#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleFederal State Budget Institutio…Phase 2

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

Crigler-Najjar Syndrome Type I · Crigler-Najjar Syndrome Type I

#Crigler-NajjarSyndromeTypeI#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleInstitut National de la Santé E…Phase 1

Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes (Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy-vMCO-010 (Gene Therapy-vMCO-010)

Stargardt Disease · Stargardt Disease

#StargardtDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleTippi MackenziePhase 1

Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase (Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase)

GM1 Gangliosidoses; GM1 Gangliosidosis, Type I · GM1 Gangliosidoses

#GM1Gangliosidoses#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Zhongshan HospitalPhase 1

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

HCC · HCC

#HCC#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Zhongshan HospitalPhase 1

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）)

HCC · HCC

#HCC#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleCelgenePhase 3

Gene-modified (GM, Gene-modified, Gene-modified (GM) T cell therapy)

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting

43 / 59 pages

← PreviousNext →